Shen Zhen Bei Ke Lian Pharmaceutical Sci-Tech

Shenzhen Beikelian Pharmaceutical Science & Technology is a clinical-stage biotechnology company headquartered in Shenzhen, China, specializing in the development of advanced cell-based immunotherapies. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) technologies designed to treat refractory hematological malignancies such as leukemia and multiple myeloma. Beikelian operates as a specialized R&D entity within the broader Beike Biotechnology ecosystem, leveraging extensive experience in cell processing and clinical translation. Their lead programs include targeted CAR-T therapies that have demonstrated promising efficacy in early-to-mid-stage clinical trials conducted in collaboration with major Chinese medical institutions. The company is committed to advancing regenerative medicine and precision oncology through innovative genetic engineering and cellular manufacturing processes.